Chalcogen Attached Indirectly To The Tetrazole Ring By Nonionic Bonding Patents (Class 548/252)
  • Publication number: 20040024024
    Abstract: This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
    Type: Application
    Filed: November 12, 2002
    Publication date: February 5, 2004
    Inventors: John N. Freskos, Y vette M. Fobian, Alok K. Awasthi, Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Nizal S. Chandrakumar, Gary A. DeCrescenzo, Bipin N. Desai, Marcia I. Heron, Susan L. Hockerman, Sara M. Jull, Darren J. Kassab, Steve A. Kolodziej, Joseph McDonald, Deborah A. Mischke, Patrick B. Mullins, Monica B. Norton, Joseph G. Rico, John J. Talley, Mahima Trivedi, Clara I. Villamil, Lijuan Jane Wang
  • Publication number: 20040010011
    Abstract: The invention relates to benzofuran or benzothiophene derivatives of general formula: 1
    Type: Application
    Filed: February 20, 2003
    Publication date: January 15, 2004
    Inventors: Jean-Louis Assens, Claude Bernhart, Frederique Cabanel-Haudricourt, Dino Nisato
  • Patent number: 6673780
    Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: January 6, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20040002485
    Abstract: A compound of the formula (I): 1
    Type: Application
    Filed: June 18, 2003
    Publication date: January 1, 2004
    Inventors: Toshio Fujishita, Tomokazu Yoshinaga, Akihiko Sato
  • Publication number: 20040002523
    Abstract: This invention relates to compounds having the Formula I: 1
    Type: Application
    Filed: June 9, 2003
    Publication date: January 1, 2004
    Applicant: Euro-Celtique S.A.
    Inventors: Derk J. Hogenkamp, Phong Nguyen, Ji Yang
  • Publication number: 20030216258
    Abstract: Condensed heterocyclic compounds of the general formula: 1
    Type: Application
    Filed: April 25, 2003
    Publication date: November 20, 2003
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Minoru Takano, Shinichi Kawamura, Takashi Komori
  • Publication number: 20030216571
    Abstract: The present invention is to provide novel tricyclic compounds having leukotriene antagonistic action and represented by the formula: 1
    Type: Application
    Filed: July 31, 2002
    Publication date: November 20, 2003
    Inventors: Yoshiaki Kuroki, Hitoshi Ueno, Tetsushi Katsube, Tetsuo Kawaguchi, Eiji Okanari, Takashi Ikuta
  • Patent number: 6649643
    Abstract: Imidazol-4-ylmethanols and their uses for preventing and treating primary tumors, metastasis and recurrence of tumors, various symptoms accompanying tumors, prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterine myoma, mastopathy and polycystic ovary syndrome are disclosed.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: November 18, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
  • Publication number: 20030212119
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 18, 2002
    Publication date: November 13, 2003
    Inventors: Jesper Lau, Inge Thoger Christensen, Peter Madsen, Carsten Behrens
  • Publication number: 20030203889
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Publication number: 20030203946
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: May 17, 2002
    Publication date: October 30, 2003
    Inventors: Carsten Behrens, Jesper Lau, Peter Madsen
  • Patent number: 6635634
    Abstract: This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: October 21, 2003
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kiyoshi Taniguchi, Minoru Sakurai, Naoaki Fujii, Kumi Hosoi, Yasuyo Tomishima, Hisashi Takasugi, Hajime Sogabe, Hirofumi Ishikawa, Naomi Hanioka
  • Patent number: 6630497
    Abstract: A class of 1-phenyl imidazol-2-one biphenylmethyl compounds is described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula wherein each of R1, R2 and R3 is independently selected from hydrido, alkyl, alkoxy, cyano, halo, hydroxy, carboxyl, alkoxycarbonyl, formyl and acetyl; alkylcarbonyl and haloalkylcarbonyl; with the proviso that at least one of R1, R2 and R3 must be a substituent other than hydrido, and with the further proviso that when each of R1 and R3 is hydrido, then R2 cannot be chloro; wherein R4 is hydrido; wherein R5 is alkyl; and wherein R6 is tetrazolyl; or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: October 7, 2003
    Assignee: G.D. Searle & Co
    Inventors: David B. Reitz, Robert E. Manning
  • Publication number: 20030181499
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: September 30, 2002
    Publication date: September 25, 2003
    Inventors: Toshio Fujishita, Tomokazu Yoshinaga
  • Patent number: 6624167
    Abstract: Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can be treated using pharmaceutical compositions incorporating compounds in which an aromatic ring is bridged with an ethylenic or acetylenic unit to an azabicyclic moiety.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: September 23, 2003
    Assignee: Targacept, Inc.
    Inventors: Thomas Jeffrey Clark, Balwinder Singh Bhatti
  • Patent number: 6620826
    Abstract: Novel N-phenyl imidazole derivatives, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: September 16, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: John Duncan Elliott, Joseph Weinstock, Jia-Ning Xiang
  • Publication number: 20030158155
    Abstract: A compound of the formula (1): 1
    Type: Application
    Filed: October 15, 2002
    Publication date: August 21, 2003
    Inventors: Yozo Hori, Fumihiko Watanabe, Hiroshige Tsuzuki, Shingo Furue, Yoshinori Tamura
  • Patent number: 6608059
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: August 19, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert A. Daines, Israil Pendrak
  • Patent number: 6608210
    Abstract: A method for producing a compound represented by the formula: wherein the ring A is a benzene ring which may be substituted in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; X is a direct bond or a spacer having an atomic length or two or less between the phenylene group and the phenyl group; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or a group convertible thereinto; n is an integer of 1 or 2; or a salt thereof, which comprises deprotecting a compound represented by the formula: wherein R is triphenylmethyl, 2-tetrahydropyranyl, methoxymethyl or ethoxy methyl, the other symbols as defined above; or a salt thereof.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: August 19, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Takehiko Naka, Kohei Nishikawa, Takeshi Kato
  • Publication number: 20030144282
    Abstract: This invention provides substituted indole compounds of the general formula: 1
    Type: Application
    Filed: November 22, 2002
    Publication date: July 31, 2003
    Applicant: Wyeth
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Publication number: 20030139376
    Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): 1
    Type: Application
    Filed: October 22, 2002
    Publication date: July 24, 2003
    Applicant: Schering Aktiengesellschaft
    Inventors: John G. Bauman, William J. Guilford, John F. Parkinson, Werner Skuballa, Babu Subramanyam
  • Publication number: 20030130239
    Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives.
    Type: Application
    Filed: October 29, 2002
    Publication date: July 10, 2003
    Applicant: Allergan, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Patent number: 6589914
    Abstract: The dihalopropene compounds of the general formula (I) have excellent insecticidal/acaricidal activity, so that they are satisfactorily effective for the control of noxious insects, mites and ticks.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: July 8, 2003
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Noriyasu Sakamoto, Sanshiro Matsuo, Masaya Suzuki, Taro Hirose, Kazunori Tsushima, Kimitoshi Umeda
  • Patent number: 6590105
    Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: July 8, 2003
    Assignee: Warner-Lambert Company
    Inventors: Stuart E. Bradley, Eric W. Collington, Matthew C. Fyfe, Martin J. Procter, Colin P. Sambrook Smith
  • Patent number: 6589970
    Abstract: This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: Wherein: Ar is phenyl, naphthyl, furanyl, benzofuranyl, indolyl, pyrazolyl, oxazolyl, fluorenyl, phenylcycloalkane where the cycloalkane can be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and Ar can be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 alkoxy, hydroxy, phenyl-(CH2)0-6—, phenyl-(CH2)0-6O—, C3-C6 cycloalkyl, —(CH2)—C3-C6 cycloalkyl, halogen, C1-C3 perflouroalkyl and C1-C3 perfluoroalkoxy where phenyl can be substituted with from 1 to 3 groups selected from C1-C6 alkyl, C1-C6 alkoxy, phenyl, halogen, trifluoromethyl or trifluoromethoxy; R1 is hydrogen, C1-C6 alkyl or phenyl-(CH2)1-6— where phenyl can be substituted with C1-C6 alkyl, C1-C6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R2 and R3 are H, C1-C6 alkyl, phenyl-(CH2)0-3—, halo and C1-C3 perflu
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: July 8, 2003
    Assignee: Wyeth
    Inventors: Thomas Joseph Commons, Susan Christman Croce, Richard Page Woodworth, Eugene John Trybulski, Hassan Mahmoud Elokdah, David LeRoy Crandall
  • Publication number: 20030125304
    Abstract: The present invention relates to compounds of the general formula I
    Type: Application
    Filed: November 4, 2002
    Publication date: July 3, 2003
    Inventors: Hans-Ulrich Demuth, Ulrich Heiser, Torsten Hoffmann, Andre Niestroj
  • Patent number: 6586462
    Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an &agr; bonds, the solid triangle represents a &bgr; bond, the wavy segments represent &agr; or &bgr; bond, dashed lines represent a double bond or a single bond R, , R1, R2 and R3 are as defined in the specification.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: July 1, 2003
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Publication number: 20030116059
    Abstract: Lightfast additives for inkjet inks are provided. These additives exhibit excellent lightfastness of many dyestuffs (both water-soluble and water-insoluble). The lightfast additives exhibit good water solubility and significant effect on dye and pigment molecules which fade most when exposed to UV, ambient light, etc., and are suitable for improving permanence of inkjet inks, including thermal inkjet ink, piezo inkjet ink, and the like. The lightfast additive comprises a molecule which is composed of three parts or moieties: A-X—B, where (a) moiety A is an aryl sulfonic acid or aryl carboxylic acid, either in acid form or salt form, with or without substituents (e.g.
    Type: Application
    Filed: November 26, 2002
    Publication date: June 26, 2003
    Inventors: Khe C. Nguyen, Sivapackia Ganapathiappan
  • Publication number: 20030105333
    Abstract: Disclosed are molecules that activate an RXR receptor, wherein the molecule comprises an RXR binding portion which binds the RXR receptor and comprises a side pocket contacting residue which contacts a side-pocket 1 of an RXR receptor.
    Type: Application
    Filed: March 8, 2002
    Publication date: June 5, 2003
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea N. Fanjul, David P.M. Pleynet, Lyle W. Spruce, Richard Fine, James W. Zapf, Jianhua Guo, Karine Jakubowicz-Jaillardon
  • Publication number: 20030105148
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: August 9, 2002
    Publication date: June 5, 2003
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 6569888
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt, in vivo hydrolysable ester, or an N—C1-6alkyl or N,N-di-(C1-6alkyl)amide thereof, where X is CH2 or SO2; R1 is an aryl optionally substituted by alkyl, alkenyl, alkynyl, halo, haloalkyl including perhaloalkyl such as trifluoromethyl, mercapto, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, hydroxyalkoxy, alkoxyalkoxy, alkanoyl, alkanoyloxy, cyano, nitro, amino, mono- or di-alkyl amino, oximino, sulphonamido, carbamoyl, mono or dialkylcarbamoyl or S(O)mR21 where m is defined above and R21 is hydrocarbyl; R4 is a group OR15 or S(O)qR15, where q is 0, 1 or 2 and R15 is a hydrogen-containing alkyl group substituted by at least one functional group as defined below, or an aryl group which is optionally substituted by one or more functional groups as defined below; and R2, R3, R5, R6 and R7 are specified organic groups.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: May 27, 2003
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Alan W Faull
  • Publication number: 20030083359
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 10, 2002
    Publication date: May 1, 2003
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • Patent number: 6555559
    Abstract: The present invention provides novel PGI2 derivatives and an anti Helicobacter agent, a platelet function potentiating agent or a cervical ripening agent containing any of the derivatives.
    Type: Grant
    Filed: August 1, 2000
    Date of Patent: April 29, 2003
    Assignee: Toray Industries, Inc.
    Inventors: Hisanori Wakita, Naohiro Yamada, Hitoshi Hatakeyama, Takeshi Ishigaki, Noriyuki Hirano, Takeshi Mori
  • Publication number: 20030078434
    Abstract: A composition for treating or preventing glomerulopathy which contains a compound of the formula (1): 1
    Type: Application
    Filed: June 6, 2002
    Publication date: April 24, 2003
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hidetake Kurihara, Fumihiko Watanabe, Yoshinori Tamura, Toshihiro Sinosaki
  • Publication number: 20030078239
    Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Application
    Filed: October 11, 2001
    Publication date: April 24, 2003
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 6552051
    Abstract: Novel compounds are provided having the structural formula R[—N(NO2)—L—R1]n wherein R, L, R1 and n are defined herein. The compounds are useful in a variety of contexts, but are primarily to be used as high energy oxidizing agents in explosive compositions, propellant formulations, gas-generating compositions and the like. The compounds are also useful as pharmaceutical agents. Compositions containing the compounds are also provided, including energetic compositions, as are methods for using the novel compounds and compositions.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: April 22, 2003
    Assignee: SRI International
    Inventors: Jeffrey C. Bottaro, Robert J. Schmitt, Mark A. Petrie, Paul E. Penwell
  • Patent number: 6541638
    Abstract: The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: April 1, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Denise Blum, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Bernd Michael Loeffler, Ulrike Obst, Sabine Wallbaum
  • Patent number: 6531485
    Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: March 11, 2003
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Paul A. DaSilva-Jardine
  • Publication number: 20030045560
    Abstract: This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1
    Type: Application
    Filed: June 13, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Susan Christman Croce, Richard Page Woodworth, Eugene John Trybulski, Hassan Mohmoud Elokdah, David LeRoy Crandall
  • Publication number: 20030040535
    Abstract: The present invention relates to tetrazole compounds of Formula 1, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs.
    Type: Application
    Filed: June 21, 2002
    Publication date: February 27, 2003
    Inventors: Gary E. Aspnes, Yuan-Ching P. Chiang
  • Publication number: 20030027853
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1
    Type: Application
    Filed: June 14, 2001
    Publication date: February 6, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Publication number: 20030022865
    Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Application
    Filed: October 11, 2001
    Publication date: January 30, 2003
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20030023096
    Abstract: The naphthyloxyacetic acid derivatives of the formula (I) 1
    Type: Application
    Filed: December 19, 2001
    Publication date: January 30, 2003
    Inventors: Yuuki Nagao, Kazuhiko Torisu, Nobuyuki Hamanaka
  • Publication number: 20030018199
    Abstract: A process is provided for preparing chiral diol sulfones of the structure 1
    Type: Application
    Filed: May 30, 2002
    Publication date: January 23, 2003
    Inventors: Paul R. Brodfuehrer, Thomas R. Sattelberg, Joydeep Kant, Xinhua Qian
  • Patent number: 6509364
    Abstract: The present invention provides novel compounds represented by the general formula I. and pharmaceutically acceptable salts thereof wherein m, n, X, R, R1 and R2 are as defined in the specification. The novel compounds are PGF2&agr; antagonists, useful in pharmaceutical compositions for treating PGF2&agr;-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: January 21, 2003
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Yariv Donde, Michael E. Garst
  • Publication number: 20030008895
    Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Application
    Filed: December 16, 1999
    Publication date: January 9, 2003
    Inventors: KIMBERLY O CAMERON, PAUL A. DASILVA-JARDINE
  • Publication number: 20020198246
    Abstract: An agent for preventing and/or treating sinusitis, comprising, as an active ingredient, a compound of the formula (I): 1
    Type: Application
    Filed: July 16, 2002
    Publication date: December 26, 2002
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kenichi Hisamatsu, Keisuke Masuyama
  • Publication number: 20020193596
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: October 30, 2001
    Publication date: December 19, 2002
    Applicant: University of Pittsburgh
    Inventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Greg B. Donner, Stephen A. Fakhoury, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Bruce G. Szczepankiewicz, Indrani W. Gunawardana
  • Publication number: 20020193411
    Abstract: A compound of formula (I): 1
    Type: Application
    Filed: May 23, 2002
    Publication date: December 19, 2002
    Inventors: Jamin Huang, Scot Kevin Huber
  • Patent number: 6495546
    Abstract: Propanolamine derivatives represented by the following formula (I): These derivatives may be &bgr;3 agonists and exert sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-urinary incontinence and anti-pollakiuria activities. Pharmaceutical compositions containing such propanolamine derivatives, methods for the prevention and/or treatment diseases using these propanolamine derivatives, and processes for their preparation are also described.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: December 17, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kiyoshi Taniguchi, Minoru Sakurai, Naoaki Fujii, Kumi Hosoi, Yasuyo Tomishima, Hisashi Takasugi, Hajime Sogabe, Hirofumi Ishikawa, Naomi Hanioka